[go: up one dir, main page]

ES2108371T3 - Nuevos derivados de estradieno de 11-benzaldoxima, procedimientos para su produccion y farmacos conteniendo estos compuestos. - Google Patents

Nuevos derivados de estradieno de 11-benzaldoxima, procedimientos para su produccion y farmacos conteniendo estos compuestos.

Info

Publication number
ES2108371T3
ES2108371T3 ES94250178T ES94250178T ES2108371T3 ES 2108371 T3 ES2108371 T3 ES 2108371T3 ES 94250178 T ES94250178 T ES 94250178T ES 94250178 T ES94250178 T ES 94250178T ES 2108371 T3 ES2108371 T3 ES 2108371T3
Authority
ES
Spain
Prior art keywords
compounds
new derivatives
benzaldoxima
estradiene
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94250178T
Other languages
English (en)
Inventor
Gerd Dr Schubert
Gunther Dr Kaufmann
Lothar Dr Sobeck
Michael Prof Dr Oettel
Walter Dr Elger
Anatoli Dr Kurischko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Application granted granted Critical
Publication of ES2108371T3 publication Critical patent/ES2108371T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN NUEVOS DERIVADOS 11 DE LA FORMULA GENERAL I Y SUS SALES EXTRAIBLES FARMACEUTICAMENTE, UN PROCESO PARA SU ELABORACION Y LOS MEDICAMENTOS QUE CONTIENEN ESTOS COMPUESTOS. LOS COMPUESTOS DESCRITOS MUESTRAN EFECTOS ANTIGESTAGENOS FUERTES CON ACTIVIDAD DISMINUIDA GLUCOCORTICOIDE.
ES94250178T 1993-09-20 1994-07-07 Nuevos derivados de estradieno de 11-benzaldoxima, procedimientos para su produccion y farmacos conteniendo estos compuestos. Expired - Lifetime ES2108371T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4332283A DE4332283A1 (de) 1993-09-20 1993-09-20 Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US08/309,175 US5693628A (en) 1993-09-20 1994-09-20 11-benzaldoxime-estra-diene derivatives, methods for their production and pharmaceuticals containing these compounds

Publications (1)

Publication Number Publication Date
ES2108371T3 true ES2108371T3 (es) 1997-12-16

Family

ID=25929786

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94250178T Expired - Lifetime ES2108371T3 (es) 1993-09-20 1994-07-07 Nuevos derivados de estradieno de 11-benzaldoxima, procedimientos para su produccion y farmacos conteniendo estos compuestos.

Country Status (16)

Country Link
US (1) US5693628A (es)
EP (1) EP0648778B1 (es)
JP (1) JP2753562B2 (es)
AT (1) ATE156835T1 (es)
AU (1) AU682195B2 (es)
CA (1) CA2130516C (es)
CZ (1) CZ292298B6 (es)
DE (2) DE4332283A1 (es)
DK (1) DK0648778T3 (es)
ES (1) ES2108371T3 (es)
FI (1) FI113657B (es)
HU (1) HU223339B1 (es)
NO (1) NO304989B1 (es)
NZ (1) NZ264229A (es)
PL (1) PL183181B1 (es)
SK (1) SK280137B6 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
DE19548450A1 (de) * 1995-12-22 1997-06-26 Jenapharm Gmbh 17alpha-Cyanomethylestra-4,9-dien-3-on-17beta-yl- derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
PE20010581A1 (es) 1999-08-31 2001-06-04 Schering Ag Mesoprogestinas (modulares de receptores de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (hrt)
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
CO5200772A1 (es) * 1999-08-31 2002-09-27 Jenapharm Gmbh And Co Kg Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes
CN1384748A (zh) * 1999-08-31 2002-12-11 耶拿制药两合公司 作为女性避孕药成分的中孕酮(孕酮受体调节剂)
DE19961219A1 (de) * 1999-12-15 2001-07-19 Jenapharm Gmbh 11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
JP4593754B2 (ja) * 2000-10-13 2010-12-08 一般財団法人 化学物質評価研究機構 化学物質の５０％阻害濃度決定方法
DE10056675A1 (de) 2000-11-10 2002-05-16 Jenapharm Gmbh Verfahren zur Herstellung von 4-(17alpha-Methylsubstituierten 3-Oxoestra-4,9-dien-11ß-yl)-benzaldehyd-(1E oder 1Z)-oximen
DE10056676A1 (de) * 2000-11-10 2002-05-16 Jenapharm Gmbh Verfahren zur Herstellung von 4-/17alpha-substituierten-3-oxoestra-4,9-dien-11beta-yl)benzaldehyd-(1E oder 1Z)-oximen
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2273061T3 (es) * 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
DE10236405A1 (de) * 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
US20050215536A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/ progestin treatment
DE102005059222B4 (de) * 2005-12-08 2007-10-11 Bayer Schering Pharma Ag 11ß-Benzaldoximderivate von D-Homoestra-4,9-dien-3-onen
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
EP2078032B1 (en) 2006-10-24 2017-08-02 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
PH12012501812A1 (en) 2010-03-22 2012-12-10 Allergan Pharmaceuticals Int Ltd Compositions and methods for non-toxic delivery of antiprogestins
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
DE3866410D1 (de) * 1987-04-24 1992-01-09 Akzo Nv 11-arylestranderivate und 11-arylpregnanderivate.
DD287510A5 (de) * 1989-04-19 1991-02-28 Adw,Zi Fuer Mikrobiologie Und Experimentelle Therapie,De Verfahren zur herstellung von 17 alpha-ch tief 2x-substituierten 11 beta-aryl-4,9-diensteroiden
DK0411733T3 (da) * 1989-08-04 1999-06-28 Schering Ag 11-beta-aryl-gona-4,9-dien-3-oner
US5276023A (en) * 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
DD289539A5 (de) * 1989-10-12 1991-05-02 Zi F. Mikrobiologie U. Experimentelle Therapie,De Verfahren zur herstellung von 11 beta-(4-acetylphenyl)-17alpha-alkoxy-methyl-estra-4,9-dien-3-onen
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds

Also Published As

Publication number Publication date
AU7035094A (en) 1995-03-30
AU682195B2 (en) 1997-09-25
PL305092A1 (en) 1995-04-03
CA2130516C (en) 2003-04-15
DE4332283A1 (de) 1995-04-13
CA2130516A1 (en) 1995-03-21
CZ197094A3 (en) 1995-04-12
NO304989B1 (no) 1999-03-15
ATE156835T1 (de) 1997-08-15
FI943687L (fi) 1995-03-21
JP2753562B2 (ja) 1998-05-20
CZ292298B6 (cs) 2003-09-17
EP0648778A3 (de) 1995-08-09
FI113657B (fi) 2004-05-31
FI943687A0 (fi) 1994-08-09
DE59403717D1 (de) 1997-09-18
EP0648778B1 (de) 1997-08-13
HU9402694D0 (en) 1994-11-28
DK0648778T3 (da) 1998-03-30
HUT68029A (en) 1995-05-29
NZ264229A (en) 1995-04-27
SK280137B6 (sk) 1999-08-06
NO942953L (no) 1995-03-21
NO942953D0 (no) 1994-08-09
HU223339B1 (hu) 2004-06-28
US5693628A (en) 1997-12-02
SK95794A3 (en) 1995-04-12
JPH07149789A (ja) 1995-06-13
EP0648778A2 (de) 1995-04-19
PL183181B1 (pl) 2002-06-28

Similar Documents

Publication Publication Date Title
ES2108371T3 (es) Nuevos derivados de estradieno de 11-benzaldoxima, procedimientos para su produccion y farmacos conteniendo estos compuestos.
ES2102144T3 (es) Nuevos derivados de estradieno de 11-benzaldoxima-17beta metoxi-17alfa-metoximetilo un procedimiento para su produccion y productos medicinales que contienen estos compuestos.
ES557835A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
ES2090713T3 (es) Sales organicas de n,n'-diacetil-cistina.
MX9307779A (es) Compuestos benzoicos fundidos.
ES8504140A1 (es) Procedimiento para la preparacion de nuevos bencimidazoles substituidos
PT83647B (pt) Processo para a preparacao de novos derivados de benzimidazole com actividade farmacologica e de composicoes farmaceuticas que os contem
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CS145091A3 (en) Isoxazole-4-carboxamides and amides of hydroxyalkylidene cyanacetic acid, medicaments comprising said compounds and their application
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
MX9206503A (es) Nuevos derivados de lupano, proceso para su preparacion y composicion farmaceutica que los contiene.
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
NO174877C (no) Fremgangsmåte for fremstilling av et legemiddel med antitumorvirkning
ES2174629T3 (es) 14,15-ciclopropano-esteroides de la serie de los 19-nor-androstanos, procedimiento para su preparacion y formulaciones farmaceuticas que contienen estos compuestos.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
AR003451A1 (es) Derivados de piperazina, una composicion farmaceutica que los comprende, el uso de los mismos y un metodo para su preparacion.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
MX9301235A (es) DERIVADOS 1,4-DIOXINO(2,3-B)PIRIDINA. á
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
SE8405588D0 (sv) New compounds
TW364905B (en) Lactone compound and process of production thereof
ES2068497T3 (es) Derivados de urea, su produccion, y composiciones farmaceuticas que los contienen.
FR2556218B1 (fr) Produit pharmaceutique pour application locale constitue par l'association d'un principe actif medicamenteux-agent enzymatique

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 648778

Country of ref document: ES